Biolinerx could mobilise interest in CXCR4 antagonism
A phase 3 win should remind investors about other clinical-stage CXCR4 antagonists.
Noxxon nears crucial combo readout
The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.
Esmo 2018 preview – Another first-line renal cancer showdown
Once again Europe’s premier oncology meeting provides the perfect venue for big pharmas including Pfizer, Roche and Astrazeneca to showcase important pivotal study…
